About us

The Industry Association

Who we are

Nuclear Medicine Europe (ex AIPES) is a European Industrial Association working on promotion, awareness and defence of Nuclear Medicine and Molecular Healthcare in Europe. We are active in the field of Imaging and Therapy with Molecular and Radioactive Tracers. The main objective of our association in this field is to ensure the promotion of the economic and/or commercial interests of its Members, in particular, by all means allowing to increase the awareness to the benefits of the products and services they offer.

In addition to the main activity described here above, our association may represent the common interest of the Members in relation with the European Institutions, with other national and international authorities and in dealing with other scientific, educational or professional association groups or societies, such as EANMEFPIACERN.

The Association does not interfere in the activities of its Members.

Mission Statement

“Imaging & Therapy with Molecular and Radioactive Tracers”

Our Objectives:

1. Foster Innovation in nuclear medicine and molecular imaging;
2. Cooperate for appropriate regulations in all aspects of nuclear medicine missions;
3. Support and facilitate logistics and operations needs of our members;
4. Promote the value of nuclear medicine achievements;
5. Harmonization through Europe;
6. Simplification of rules and procedures.

Nuclear Medicine Europe Position on Radiopharmaceuticals: Three Pillars to Drive our Actions:

PATIENTS SAFETY
Full compliance: adoption of all relevant requirements, both on radioactivity and pharmaceuticals Compliance covers the entire process: from R&D, to manufacturing, to distribution, to any after sale events
INNOVATION

Tradition of innovation and commitment to novel, future tracers Development of new drugs will require a more tailored regulatory approach

HEALTHCARE FOR EVERYONE

Ensuring products and technology availability for millions of procedures all over Europe.

General Assembly

The General Meeting is composed of all the Members of the Grouping. Each member shall appoint an authorized representative to attend and vote on its behalf at a General Meeting. The General Assembly adopts resolutions, elects Managers of the Association and agrees to the admission of new Members. The General Meeting is composed of appointed representatives from each Member or Associate partner of the Association. Each representative has one vote and resolutions shall only be adopted by unanimous consent.

The members of the Grouping can, by a written resolution taken by unanimous consent, take all decisions which are subject to the General Meeting, out of a meeting, except for those decisions for which the adoption before a notary must be provided. Following the adoption of a resolution, the Executive Committee shall ensure that the statutory filing requirements are complied with.

  • AAA (Advanced Accelerator Applications) — Joshua Nutting, Managing Director Radiopharma; to Deborah Langhammer until further notice; Susanne Mundo
  • ARRONAX — Tony Prezeau, Directeur des Partenariats; Alternate: Ferrid Haddad; Jean-François Gestin
  • ATONCO — Sylvain Fanier, President; Adrien Reymond
  • BAYER AG (Radiopharmaceuticals) — Nelson Ambrogio, President Radiology; Alex Gibbs
  • BLUE EARTH Diagnostics Ireland Ltd. — Matthew Morrison, Commercial PET Director; Clare Gidley
  • COMECER S.p.A. — Simone Volpi, President; Martina Santandrea; Mario Malinconico
  • CURIUM Netherlands BV — Timothée de Courlon, Vice President Strategy Europe; Alternate: Roy Brown, Vice President Government Affairs & Strategic Alliances; Andre Broersen
  • ECKERT & ZIEGLER Radiopharma GmbH — Dirk Becker, Director Operations; Jan Schöpflin
  • FRAMATOME — Ralf Gathmann, Vice President Framatome; Dominique Geslin
  • GE Healthcare — Revital Melzer, Global Sourcing MI-Isotopes, PET, Generators; Alternate: Etienne Boquien, Global Business Leader Core Molecular Imaging
  • IBA S.A. — Charles Kumps, Chief Innovation & Development; Alternate: Jean-Michel Geets
  • IRE (Institut National des Radioéléments) — Erich Kollegger, CEO
  • ITM Isotope Technologies — Roger Estefanos, Biotech Executive / Theranostics
  • Johnson & Johnson Innovative Medicine — Rob Vermeulen, Director Regulatory Affairs
  • LEMERPAX — Pierre-Marie Lemer, President; Christophe Selliez, Alternate; Valérie Chevreuil
  • LANTHEUS EU Limited — Ira Goldman, Vice President Global Public Policy and Government Relations
  • LIFE COURIERS — Claude Poliart, Group Chief Executive Officer
  • LIFE MOLECULAR IMAGING — Lutz Dinkelborg, Managing Director; Nico Beukman
  • LILLY FRANCE (Avid Radiopharmaceuticals) — Angel Hijos, Director European Manufacturing Operations
  • MEDIRADIOPHARMA — Gyozo Janoki, Chairman and CEO; Melinda Kovacs
  • ORANO CHEMISTRY ENRICHMENT — Laurent Bigot, Head of Stable Isotopes Division; Elisabeth Guillaut
  • ORANOMED — Arnaud Lesegretain, President and CEO; Sophie Letournel; Elisabeth Guillaut
  • PHSE snc — Paul Rice, Chief Development Officer; Hans Van de Maele
  • POLATOM (National Centre for Nuclear Research) — Tomasz Dziel, Managing Director
  • ROTEM GmbH — Julia Möbius, General Manager
  • ROTOP PHARMAKA GmbH — Jens Junker, Managing Director
  • SHINE Technologies (Shine Europe B.V.) — Harrie Buurlage, Vice President Strategic Alliances
  • SIEMENS Healthineers — Deborah Langhammer, Vice President Molecular Imaging Europe; see also Advanced Accelerator Applications
  • SWAN ISOTOPEN (succession of Swan Isotopen AG) — Konrade von Bremen, Chief Executive Officer
  • TEMA SINERGIE — Matteo Morini, International Sales Manager
  • TELIX Belgium — Raphael Ortiz, Chief Operating Officer
  • TRASIS — Jean-Luc Morelle, CEO; Corentin Warnier
  • URENCO Stable Isotopes — Linda Ashton, Head of Isotopes
  •  

The sensitive nature of NMEU activities for the public, (i.e. human healthcare issues and radioactive hazards fear), implies at any time the risk of being the target of public inquiry and questioning. Moreover, NMEU wants to promote fair competition between its members. NMEU members should therefore at least fully comply with the EU and International legislation and principles related to:

  • Good Manufacturing Practice and Good Clinical Practice
  • Radioactive Transport Regulation
  • Radioprotection regulations for products or employees
  • Confidentiality of information
  • Patent protection
  • Fair Trade
      1. Each company should respect EU (and related EMEA and/or MDD guidelines) and local Good Manufacturing Practice (GMP) rules in the production of radiopharmaceuticals and medical equipment.
      2. Each company should respect EU (and related EMEA guidelines) and local GMP rules for the production of Investigational Medical Products (IMP) for human use.
      3. IMP for human use should only be provided to customers within the framework of a clinical study or for compassionate use and, in any case, under the express authorization from the competent authority responsible for IMP for human use
      4. No company shall sell, distribute or transport products from producers which do not respect EU and local GMP rules for the production of radiopharmaceuticals and medical equipment.
      5. No company shall sell, distribute or transport Investigational Medical Products (IMP) for human use not produced in laboratories, which are not authorized for IMP.
      6. Each company should strictly respect ADR regulations (European Agreement concerning the International Carriage of Dangerous Goods by Road) when transporting radiopharmaceuticals and IMP.
      7. Regarding their employees and products, each company should comply with ICRP (International Commission on Radiological Protection) and local radioprotection rules in the production, distribution and transportation of radiopharmaceuticals.
      8. Each company should report to NMEU any event that could trigger a crisis communication plan from the NMEU Executive Committee, in particular in view of avoiding potential EU-wide negative impact for the industry and/or customers.
      9. Each company should respect confidentiality of information and documents shared within NMEU, during and from NMEU meetings. Such confidential information cannot, in any case, be used against any NMEU member.
      10. Each company should comply with patents regulation.

Executive Committee

Mart-Jan Blauwhoff

President

Erich Kollegger

Vice President and Secretary General

Konrade von Bremen

Vice President and Treasurer

Matt Morrison

Vice President

Etienne Boquien

Vice President

Guy Turquet de Beauregard

Honorary President

Executive Office - Brussels

The administration office, based in Brussels, is in charge of coordination between stakeholders, and acts as a liaison office and an information platform between the Group and the other European entities.

David Crunelle

Senior Communications Advisor

Jocelyne Baldasso

Executive Administrator

History

1987
European radiopharmaceutical companies agree to form the Association of Radiopharmaceutical Producers Europe (ARPE). ARPE is formalised shortly thereafter as a European Economic Interest Group (EEIG).
1990
ARPE focuses on pharmaceutical regulation, achieving an agreement with the EEC for a rationalised registration process. ARPE becomes a central industry voice, successfully lobbying governments, regulators, and industry partners to address supply risks for critical raw materials.
Mid-1990s
Strategic collaboration begins between ARPE and the European Association of Nuclear Medicine (EANM). ARPE expands its statutes to include hardware and equipment companies. The organisation is renamed ARPES (Association of Radiopharmaceutical Producers and Equipment Suppliers).
Late 1990s
ARPES supports major EANM initiatives, including: Funding a cost-benefit study in nuclear cardiology. Contributing to a strategic vision for nuclear medicine in Europe. Most member companies transition toward multi-modality in-vivo diagnostic activities.
2001
The organisation adopts the name AIPES (Association of Imaging Producers and Imaging Suppliers). Mission expands to foster industry collaboration across all in-vivo diagnostic fields.
May 2019
AIPES rebrands as Nuclear Medicine Europe, adopting a new name and visual identity.